Filing Details

Accession Number:
0001055947-11-000045
Form Type:
4
Zero Holdings:
No
Publication Time:
2011-12-05 17:52:56
Reporting Period:
2011-11-23
Filing Date:
2011-12-05
Accepted Time:
2011-12-05 17:52:56
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1100412 Array Biopharma Inc ARRY Pharmaceutical Preparations (2834) 841460811
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
918923 P L Fund Value Biotechnology 900 N. Michigan Ave., Suite 1100
Chicago IL 60611
No No No Yes
1055947 P/Il L Partners Bvf 900 N. Michigan Ave., Suite 1100
Chicago IL 60611
No No Yes No
1056807 Bvf Inc/Il 900 N. Michigan Ave., Suite 1100
Chicago IL 60611
No No Yes No
1102444 Biotechnology Value Fund Ii Lp 900 N. Michigan Ave., Suite 1100
Chicago IL 60611
No No No Yes
1132245 Bvf Investments Llc 900 N. Michigan Ave., Suite 1100
Chicago IL 60611
No No No Yes
1233840 N Mark Lampert 900 N. Michigan Ave., Suite 1100
Chicago IL 60611
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2011-11-23 15,253 $2.21 1,689,469 No 4 P Indirect See Explanation of Responses
Common Stock Acquisiton 2011-11-23 11,000 $2.21 1,036,700 No 4 P Indirect See Explanation of Responses
Common Stock Acquisiton 2011-11-23 38,000 $2.21 4,813,400 No 4 P Indirect See Explanation of Responses
Common Stock Acquisiton 2011-12-01 17,600 $2.04 1,707,069 No 4 P Indirect See Explanation of Responses
Common Stock Acquisiton 2011-12-01 9,200 $2.04 1,045,900 No 4 P Indirect See Explanation of Respones
Common Stock Acquisiton 2011-12-01 56,400 $2.04 4,869,800 No 4 P Indirect See Explanation of Responses
Common Stock Acquisiton 2011-12-02 7,200 $2.10 1,714,269 No 4 P Indirect See Explanation of Responses
Common Stock Acquisiton 2011-12-02 4,400 $2.10 1,050,300 No 4 P Indirect See Explanation of Responses
Common Stock Acquisiton 2011-12-02 20,500 $2.10 4,890,300 No 4 P Indirect See Explanation of Responses
Common Stock Acquisiton 2011-12-05 1,000 $2.14 1,715,269 No 4 P Indirect See Explanation of Responses
Common Stock Acquisiton 2011-12-05 600 $2.14 1,050,900 No 4 P Indirect See Explanation of Responses
Common Stock Acquisiton 2011-12-05 2,700 $2.14 4,893,000 No 4 P Indirect See Explanation of Responses
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect See Explanation of Responses
No 4 P Indirect See Explanation of Responses
No 4 P Indirect See Explanation of Responses
No 4 P Indirect See Explanation of Responses
No 4 P Indirect See Explanation of Respones
No 4 P Indirect See Explanation of Responses
No 4 P Indirect See Explanation of Responses
No 4 P Indirect See Explanation of Responses
No 4 P Indirect See Explanation of Responses
No 4 P Indirect See Explanation of Responses
No 4 P Indirect See Explanation of Responses
No 4 P Indirect See Explanation of Responses
Footnotes
  1. This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), BVF Investments, L.L.C. ("BVFLLC"), BVF Partners L.P. ("Partners"), BVF Inc., and Mark Lampert (collectively the "Reporting Persons"). Each of the Reporting Persons may be deemed to be a member of a section 13G group that collectively owns more than 10% of the Issuer's oustanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the shares of Common Stock reported herein except to the extent of his or its pecuniary interest therein.
  2. Represents shares of Common Stock owned directly by BVF. As the general partner of BVF, Partners may be deemed to beneficially own the shares of Common Stock owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc., may be deemed to beneficially own the shares of Common Stock owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the shares of Common Stock owned directly by BVF.
  3. Represents shares of Common Stock owned directly by BVF2. As the general partner of BVF2, Partners may be deemed to beneficially own the shares of Common Stock owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc., may be deemed to beneficially own the shares of Common Stock owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the shares of Common Stock owned directly by BVF2.
  4. Represents shares of Common Stock owned directly by BVFLLC. As the manager of BVFLLC, Partners may be deemed to beneficially own the shares of Common Stock owned directly by BVFLLC. As the investment adviser and general partner of Partners, BVF Inc., may be deemed to beneficially own the shares of Common Stock owned directly by BVFLLC. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the shares of Common Stock owned directly by BVFLLC.
  5. Units may represent aggregation of daily trade activity. Details regarding individual execution amounts and prices are available upon request
  6. The shares of Common Stock are directly beneficially owned by BVF Investments, L.L.C., a Delaware limited liability company. Pursuant to the operating agreement of BVFLLC, BVF Partners, L.P., a Delaware limitedpartnership is authorized, among other things, to invest the contributed capital of Samana Capital, L.P., the majority member of BVFLLC, in the shares of Common Stock and other securities and to vote, exercise or convert anddispose of such securities and is entitled to receive fess based on assets under management and, subject to certain exceptions, allocations based on realized and unrealized gains on such assets.